Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 109 entries
Sorted by: Best Match Show Resources per page
Genetic Analysis of Recombination-Deficient Mutants of Escherichia coli K-12 Carrying rec Mutations Cotransducible with thyA

k-12

Mount DW.
GSID: n7RBeagKjLkJ
NS Willetts, DW Mount - Journal of Bacteriology, 1969 - Am Soc Microbiol

The rec mutations carried by 20 strains of Escherichia coli K-12 which are defective in genetic recombination and sensitive to ultraviolet light and X rays, and whose λ lysogens show spontaneous phage production, have been mapped near thyA. In...

Cite
Willetts, N. S., & Mount, D. W. (1969). Genetic analysis of recombination-deficient mutants of Escherichia coli K-12 carrying rec mutations cotransducible with thyA. Journal of Bacteriology, 100(2), 923-934.
Willetts, Neil S., and David W. Mount. "Genetic analysis of recombination-deficient mutants of Escherichia coli K-12 carrying rec mutations cotransducible with thyA." Journal of Bacteriology 100.2 (1969): 923-934.
Copy Download .nbib Format: MLA
Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy.

Kidney international reports

Sise ME, Wisocky J, Rosales IA, Chute D, Holmes JA, Corapi KM, Babitt JL, Tangren JS, Hashemi N, Lundquist AL, Williams WW, Mount DB, Andersson KL, Rennke HG, Smith RN, Colvin R, Thadhani RI, Chung RT.
PMID: 27990496
Kidney Int Rep. 2016 Sep;1(3):135-143. doi: 10.1016/j.ekir.2016.06.006.

Novel, all-oral interferon-free direct-acting antiviral agents have revolutionized the management of hepatitis C virus (HCV) infection by producing exceptional cure rates with minimal adverse events. While provocation or exacerbation of autoimmunity has been reported in HCV-infected patients receiving interferon,...

Cite
Sise ME, Wisocky J, Rosales IA, et al. Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. Kidney Int Rep. 2016;1(3):135-143doi: 10.1016/j.ekir.2016.06.006.
Sise, M. E., Wisocky, J., Rosales, I. A., Chute, D., Holmes, J. A., Corapi, K. M., Babitt, J. L., Tangren, J. S., Hashemi, N., Lundquist, A. L., Williams, W. W., Mount, D. B., Andersson, K. L., Rennke, H. G., Smith, R. N., Colvin, R., Thadhani, R. I., & Chung, R. T. (2016). Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. Kidney international reports, 1(3), 135-143. https://doi.org/10.1016/j.ekir.2016.06.006
Sise, Meghan E, et al. "Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy." Kidney international reports vol. 1,3 (2016): 135-143. doi: https://doi.org/10.1016/j.ekir.2016.06.006
Sise ME, Wisocky J, Rosales IA, Chute D, Holmes JA, Corapi KM, Babitt JL, Tangren JS, Hashemi N, Lundquist AL, Williams WW, Mount DB, Andersson KL, Rennke HG, Smith RN, Colvin R, Thadhani RI, Chung RT. Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. Kidney Int Rep. 2016 Sep;1(3):135-143. doi: 10.1016/j.ekir.2016.06.006. PMID: 27990496; PMCID: PMC5155703.
Copy Download .nbib Format: NLM
Introduction.

Environmental monitoring and assessment

Mouat DA, Hutchinson CF, McClure BC.
PMID: 24197836
Environ Monit Assess. 1995 Jan;37(1):1-4. doi: 10.1007/BF00546876.

No abstract available.

Cite
Mouat DA, Hutchinson CF, McClure BC. Introduction. Environ Monit Assess. 1995;37(1):1-4doi: 10.1007/BF00546876.
Mouat, D. A., Hutchinson, C. F., & McClure, B. C. (1995). Introduction. Environmental monitoring and assessment, 37(1), 1-4. https://doi.org/10.1007/BF00546876
Mouat, D A, et al. "Introduction." Environmental monitoring and assessment vol. 37,1 (1995): 1-4. doi: https://doi.org/10.1007/BF00546876
Mouat DA, Hutchinson CF, McClure BC. Introduction. Environ Monit Assess. 1995 Jan;37(1):1-4. doi: 10.1007/BF00546876. PMID: 24197836.
Copy Download .nbib Format: NLM
Compact far ultraviolet emission source with rich spectral emission 1150-3100 A.

Applied optics

Mount GH, Yamasaki G, Fowler W, Fastie WG.
PMID: 20168548
Appl Opt. 1977 Mar 01;16(3):591-5. doi: 10.1364/AO.16.000591.

A new compact far uv emission source suitable for laboratory or space applications is described. The source is small, rugged, lightweight, spectrally rich, and bright in the 1150-3200-A region. It has met rigid spacecraft environmental tests and also is...

Cite
Mount GH, Yamasaki G, Fowler W, et al. Compact far ultraviolet emission source with rich spectral emission 1150-3100 A. Appl Opt. 1977;16(3):591-5doi: 10.1364/AO.16.000591.
Mount, G. H., Yamasaki, G., Fowler, W., & Fastie, W. G. (1977). Compact far ultraviolet emission source with rich spectral emission 1150-3100 A. Applied optics, 16(3), 591-5. https://doi.org/10.1364/AO.16.000591
Mount, G H, et al. "Compact far ultraviolet emission source with rich spectral emission 1150-3100 A." Applied optics vol. 16,3 (1977): 591-5. doi: https://doi.org/10.1364/AO.16.000591
Mount GH, Yamasaki G, Fowler W, Fastie WG. Compact far ultraviolet emission source with rich spectral emission 1150-3100 A. Appl Opt. 1977 Mar 01;16(3):591-5. doi: 10.1364/AO.16.000591. PMID: 20168548.
Copy Download .nbib Format: NLM
Absolute S- and P-plane polarization efficiencies for high frequency holographic gratings in the VUV.

Applied optics

Caruso AJ, Mount GH, Woodgate BE.
PMID: 20332834
Appl Opt. 1981 May 15;20(10):1764-76. doi: 10.1364/AO.20.001764.

High frequency plane gratings (3500 and 3600 gr/mm) have been holographically ruled and blazed for the VUV spectral region. All gratings were coated with 70 nm Al + 25 nm MgF(2). Absolute unpolarized and S-and P-plane polarization efficiencies have...

Cite
Caruso AJ, Mount GH, Woodgate BE. Absolute S- and P-plane polarization efficiencies for high frequency holographic gratings in the VUV. Appl Opt. 1981;20(10):1764-76doi: 10.1364/AO.20.001764.
Caruso, A. J., Mount, G. H., & Woodgate, B. E. (1981). Absolute S- and P-plane polarization efficiencies for high frequency holographic gratings in the VUV. Applied optics, 20(10), 1764-76. https://doi.org/10.1364/AO.20.001764
Caruso, A J, et al. "Absolute S- and P-plane polarization efficiencies for high frequency holographic gratings in the VUV." Applied optics vol. 20,10 (1981): 1764-76. doi: https://doi.org/10.1364/AO.20.001764
Caruso AJ, Mount GH, Woodgate BE. Absolute S- and P-plane polarization efficiencies for high frequency holographic gratings in the VUV. Appl Opt. 1981 May 15;20(10):1764-76. doi: 10.1364/AO.20.001764. PMID: 20332834.
Copy Download .nbib Format: NLM
Q value of ;{115}In --> ;{115}sn(3/2;{+}): the lowest known energy beta decay.

Physical review letters

Mount BJ, Redshaw M, Myers EG.
PMID: 19792427
Phys Rev Lett. 2009 Sep 18;103(12):122502. doi: 10.1103/PhysRevLett.103.122502. Epub 2009 Sep 16.

Using precision, cryogenic, Penning-trap mass spectrometry we have measured the atomic mass difference M[;{115}In]-M[;{115}Sn] to be 497.489(10) keV/c;{2}. Combined with the energy of the 3/2;{+} first excited state of ;{115}Sn [J. Blachot, Nuclear Data Sheets 104, 967 (2005)10.1016/j.nds.2005.03.003], the...

Cite
Mount BJ, Redshaw M, Myers EG. Q value of ;{115}In --> ;{115}sn(3/2;{+}): the lowest known energy beta decay. Phys Rev Lett. 2009;103(12):122502doi: 10.1103/PhysRevLett.103.122502.
Mount, B. J., Redshaw, M., & Myers, E. G. (2009). Q value of ;{115}In --> ;{115}sn(3/2;{+}): the lowest known energy beta decay. Physical review letters, 103(12), 122502. https://doi.org/10.1103/PhysRevLett.103.122502
Mount, Brianna J, et al. "Q value of ;{115}In --> ;{115}sn(3/2;{+}): the lowest known energy beta decay." Physical review letters vol. 103,12 (2009): 122502. doi: https://doi.org/10.1103/PhysRevLett.103.122502
Mount BJ, Redshaw M, Myers EG. Q value of ;{115}In --> ;{115}sn(3/2;{+}): the lowest known energy beta decay. Phys Rev Lett. 2009 Sep 18;103(12):122502. doi: 10.1103/PhysRevLett.103.122502. Epub 2009 Sep 16. PMID: 19792427.
Copy Download .nbib Format: NLM
The effect of various drug pretreatments on the convulsions and cerebellar cyclic nucleotide changes induced by the convulsant 4-isopropyl-2,6,7-trioxa-1-phosphatbicyclo(2,2,2)octane-1-oxide(IPTBO).

Neurochemistry international

Blenkinsop IS, Coult DB, Davies WE, Howells DJ.
PMID: 20488040
Neurochem Int. 1984;6(2):211-5. doi: 10.1016/0197-0186(84)90095-0.

The effects of pretreatment of mice with some drugs which modify GABAergic neurotransmission on the convulsions and cerebellar cyclic nucelotide level changes induced by the subsequent intracerebroventricular administration of 4-isopropyl-2,6,7-trioxa-1-phosphabicyclo(2,2,2)octane-1-oxide (IPTBO) have been studied. Muscimol, pentobarbitone and diazepam reduced...

Cite
Blenkinsop IS, Coult DB, Davies WE, et al. The effect of various drug pretreatments on the convulsions and cerebellar cyclic nucleotide changes induced by the convulsant 4-isopropyl-2,6,7-trioxa-1-phosphatbicyclo(2,2,2)octane-1-oxide(IPTBO). Neurochem Int. 1984;6(2):211-5doi: 10.1016/0197-0186(84)90095-0.
Blenkinsop, I. S., Coult, D. B., Davies, W. E., & Howells, D. J. (1984). The effect of various drug pretreatments on the convulsions and cerebellar cyclic nucleotide changes induced by the convulsant 4-isopropyl-2,6,7-trioxa-1-phosphatbicyclo(2,2,2)octane-1-oxide(IPTBO). Neurochemistry international, 6(2), 211-5. https://doi.org/10.1016/0197-0186(84)90095-0
Blenkinsop, I S, et al. "The effect of various drug pretreatments on the convulsions and cerebellar cyclic nucleotide changes induced by the convulsant 4-isopropyl-2,6,7-trioxa-1-phosphatbicyclo(2,2,2)octane-1-oxide(IPTBO)." Neurochemistry international vol. 6,2 (1984): 211-5. doi: https://doi.org/10.1016/0197-0186(84)90095-0
Blenkinsop IS, Coult DB, Davies WE, Howells DJ. The effect of various drug pretreatments on the convulsions and cerebellar cyclic nucleotide changes induced by the convulsant 4-isopropyl-2,6,7-trioxa-1-phosphatbicyclo(2,2,2)octane-1-oxide(IPTBO). Neurochem Int. 1984;6(2):211-5. doi: 10.1016/0197-0186(84)90095-0. PMID: 20488040.
Copy Download .nbib Format: NLM
Effects of dose and time after administration of 4-isopropyl-2,6,7-trioxa-1-phosphabicyclo (2,2,2)octane-1-oxide (IPTBO) on cyclic nucleotide concentrations in mouse cerebellum.

Neurochemistry international

Blenkinsop IS, Coult DB, Davies WE, Howells DJ.
PMID: 20488068
Neurochem Int. 1984;6(4):453-7. doi: 10.1016/0197-0186(84)90114-1.

The concentrations of cyclic AMP and cyclic GMP in the mouse cerebellum after intracerebroventricular administration of a range of doses of IPTBO have been studied with particular interest in the temporal changes after injection. A non typical dose relationship...

Cite
Blenkinsop IS, Coult DB, Davies WE, et al. Effects of dose and time after administration of 4-isopropyl-2,6,7-trioxa-1-phosphabicyclo (2,2,2)octane-1-oxide (IPTBO) on cyclic nucleotide concentrations in mouse cerebellum. Neurochem Int. 1984;6(4):453-7doi: 10.1016/0197-0186(84)90114-1.
Blenkinsop, I. S., Coult, D. B., Davies, W. E., & Howells, D. J. (1984). Effects of dose and time after administration of 4-isopropyl-2,6,7-trioxa-1-phosphabicyclo (2,2,2)octane-1-oxide (IPTBO) on cyclic nucleotide concentrations in mouse cerebellum. Neurochemistry international, 6(4), 453-7. https://doi.org/10.1016/0197-0186(84)90114-1
Blenkinsop, I S, et al. "Effects of dose and time after administration of 4-isopropyl-2,6,7-trioxa-1-phosphabicyclo (2,2,2)octane-1-oxide (IPTBO) on cyclic nucleotide concentrations in mouse cerebellum." Neurochemistry international vol. 6,4 (1984): 453-7. doi: https://doi.org/10.1016/0197-0186(84)90114-1
Blenkinsop IS, Coult DB, Davies WE, Howells DJ. Effects of dose and time after administration of 4-isopropyl-2,6,7-trioxa-1-phosphabicyclo (2,2,2)octane-1-oxide (IPTBO) on cyclic nucleotide concentrations in mouse cerebellum. Neurochem Int. 1984;6(4):453-7. doi: 10.1016/0197-0186(84)90114-1. PMID: 20488068.
Copy Download .nbib Format: NLM
Treatment of intervertebral disc protrusion.

Canadian Medical Association journal

Mount HT.
PMID: 20311877
Can Med Assoc J. 1972 Mar 18;106(6):633-6.

No abstract available.

Cite
Mount HT. Treatment of intervertebral disc protrusion. Can Med Assoc J. 1972;106(6):633-6
Mount, H. T. (1972). Treatment of intervertebral disc protrusion. Canadian Medical Association journal, 106(6), 633-6.
Mount, H T. "Treatment of intervertebral disc protrusion." Canadian Medical Association journal vol. 106,6 (1972): 633-6.
Mount HT. Treatment of intervertebral disc protrusion. Can Med Assoc J. 1972 Mar 18;106(6):633-6. PMID: 20311877; PMCID: PMC1940508.
Copy Download .nbib Format: NLM
Music therapy in palliative care.

Canadian Medical Association journal

Mount BM.
PMID: 20313312
Can Med Assoc J. 1979 Jun 09;120(11):1327-8.

No abstract available.

Cite
Mount BM. Music therapy in palliative care. Can Med Assoc J. 1979;120(11):1327-8
Mount, B. M. (1979). Music therapy in palliative care. Canadian Medical Association journal, 120(11), 1327-8.
Mount, B M. "Music therapy in palliative care." Canadian Medical Association journal vol. 120,11 (1979): 1327-8.
Mount BM. Music therapy in palliative care. Can Med Assoc J. 1979 Jun 09;120(11):1327-8. PMID: 20313312; PMCID: PMC1819333.
Copy Download .nbib Format: NLM
OXYGEN IN THE TREATMENT OF TUBERCULOSIS.

Canadian Medical Association journal

Mount HT.
PMID: 20318437
Can Med Assoc J. 1931 Sep;25(3):309-10.

No abstract available.

Cite
Mount HT. OXYGEN IN THE TREATMENT OF TUBERCULOSIS. Can Med Assoc J. 1931;25(3):309-10
Mount, H. T. (1931). OXYGEN IN THE TREATMENT OF TUBERCULOSIS. Canadian Medical Association journal, 25(3), 309-10.
Mount, H T. "OXYGEN IN THE TREATMENT OF TUBERCULOSIS." Canadian Medical Association journal vol. 25,3 (1931): 309-10.
Mount HT. OXYGEN IN THE TREATMENT OF TUBERCULOSIS. Can Med Assoc J. 1931 Sep;25(3):309-10. PMID: 20318437; PMCID: PMC382652.
Copy Download .nbib Format: NLM
Hypertension associated with neurocognitive performance among persons with type 2 diabetes: a brief report.

Mental health in family medicine

Mount DL.
PMID: 23205065
Ment Health Fam Med. 2011 Dec;8(4):243-7.

Background Among persons with type 2 diabetes (T2DM) it is not known whether the presence of hypertension could have a detrimental effect on learning ability and whether repeated exposure to information changes the amount of information retained. The aim...

Cite
Mount DL. Hypertension associated with neurocognitive performance among persons with type 2 diabetes: a brief report. Ment Health Fam Med. 2011;8(4):243-7
Mount, D. L. (2011). Hypertension associated with neurocognitive performance among persons with type 2 diabetes: a brief report. Mental health in family medicine, 8(4), 243-7.
Mount, David L. "Hypertension associated with neurocognitive performance among persons with type 2 diabetes: a brief report." Mental health in family medicine vol. 8,4 (2011): 243-7.
Mount DL. Hypertension associated with neurocognitive performance among persons with type 2 diabetes: a brief report. Ment Health Fam Med. 2011 Dec;8(4):243-7. PMID: 23205065; PMCID: PMC3487601.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 109 entries